

## CLAIMS

I claim:

1. A product comprising a first pharmaceutically acceptable composition comprising an alpha-adrenoceptor antagonist and a second pharmaceutically acceptable composition comprising a muscarinic antagonist, wherein said product is a combined preparation for simultaneous, separate or sequential use of said first composition and said second composition.

2. The product of Claim 1 wherein said alpha-adrenoceptor antagonist in said first composition is non-selective.

3. The product of Claim 1 wherein said alpha-adrenoceptor antagonist in said first composition is selective for  $\alpha_1$  receptors.

4. The product of Claim 3 wherein said alpha-adrenoceptor antagonist in said first composition is selected from the group consisting of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, doxazosin, tetrazosin, abanoquil, prazosin, and indoramin or pharmaceutically acceptable salts thereof.

5. The product of Claim 1 wherein said muscarinic antagonist in said second composition is non-selective.

6. The product of Claim 1 wherein said muscarinic antagonist in said second composition is selective for  $M_3$  receptors.

7. The product of Claim 1 wherein said muscarinic antagonist in said second composition is selected from the group consisting of darifenacin, tolterodine and oxybutynin or pharmaceutically acceptable salts thereof.

8. The product of Claim 1 wherein said muscarinic antagonist is darifenacin or a pharmaceutically acceptable salt thereof.

9.The product of Claim 1 wherein said first composition comprises doxazosin and said second composition comprises darifenacin or a pharmaceutically acceptable salt of either thereof.

5           10.The product of Claim 1 wherein said first composition comprises 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline and said second composition comprises darifenacin or a pharmaceutically acceptable salt of either thereof.

10           11. A medicament comprising an alpha-adrenoceptor antagonist in combination with a muscarinic antagonist.

15           12.The medicament of Claim 11 wherein said alpha-adrenoceptor antagonist is non-selective.

            13.The medicament of Claim 11 wherein said alpha-adrenoceptor antagonist is selective for  $\alpha_1$  receptors.

20           14.The medicament of Claim 11 wherein said alpha-adrenoceptor antagonist is selected from the group consisting of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, doxazosin, tetrazosin, abanoquil, prazosin, and indoramin or pharmaceutically acceptable salts thereof.

25           15.The medicament of Claim 11 wherein said muscarinic antagonist is non-selective.

            16.The medicament of Claim 11 wherein said muscarinic antagonist is selective for  $M_3$  receptors.

30           17.The medicament of Claim 11 wherein said muscarinic antagonist is selected from the group consisting of darifenacin, tolterodine and oxybutynin or pharmaceutically acceptable salts thereof.

0978250102074

18. The medicament of Claim 11 wherein said muscarinic antagonist is darifenacin, or a pharmaceutically acceptable salt thereof.

5 19. The medicament of Claim 11 wherein said alpha-adrenoceptor antagonist is doxazosin and said muscarinic antagonist is darifenacin, or pharmaceutically acceptable salts of either thereof.

10 20. The medicament of Claim 11 wherein said alpha-adrenoceptor antagonist is 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline and said muscarinic antagonist is darifenacin, or pharmaceutically acceptable salts of either thereof.

15 21. A pharmaceutical composition comprising an alpha-adrenoceptor antagonist, a muscarinic antagonist and a pharmaceutically acceptable carrier.

22. The composition of Claim 21 wherein said alpha-adrenoceptor antagonist is non-selective or selective for  $\alpha_1$  receptors.

20 23. The composition of Claim 21 wherein said alpha-adrenoceptor antagonist is selected from the group consisting of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, doxazosin, tetrazosin, abanoquil, prazosin, and indoramin or pharmaceutically acceptable salts thereof.

25 24. The composition of Claim 21 wherein said muscarinic antagonist is non-selective or selective for  $M_3$  receptors.

30 25. The composition of Claim 21 wherein said muscarinic antagonist is selected from the group consisting of darifenacin, tolterodine and oxybutynin or pharmaceutically acceptable salts thereof.

26. The composition of Claim 21 wherein said muscarinic antagonist is darifenacin, or a pharmaceutically acceptable salt thereof.

27. The composition of Claim 21 wherein said alpha-adrenoceptor antagonist is doxazosin and said muscarinic antagonist is darifenacin, or pharmaceutically acceptable salts of either thereof.

5           28. The composition of Claim 21 wherein said alpha-adrenoceptor antagonist is 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline and said muscarinic antagonist is darifenacin, or pharmaceutically acceptable salts of either thereof.

10           29. A method for treating the lower urinary tract symptoms associated with benign hyperplasia in mammals comprising administering to a mammal in need thereof an effective amount of an alpha-adrenoceptor antagonist in combination with a muscarinic antagonist.

15           30. The method of Claim 29 wherein said alpha-adrenoceptor antagonist and said muscarinic antagonist is administered simultaneously.

            31. The method of Claim 29 wherein said alpha-adrenoceptor antagonist and said muscarinic antagonist is administered separately.

20           32. The method of Claim 29 wherein said alpha-adrenoceptor antagonist and said muscarinic antagonist is administered sequentially.

            33. The method of claim 29 wherein the alpha-adrenoceptor antagonist is non-selective or selective for  $\alpha_1$  receptors.

            34. The method of Claim 29 wherein said alpha-adrenoceptor antagonist is selected from the group consisting of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, doxazosin, tetrazosin, abanoquil, prazosin, and indoramin or pharmaceutically acceptable salts thereof.

            35. The method of Claim 29 wherein said muscarinic antagonist is non-selective or selective for  $M_3$  receptors.

10/02/2010 05:23:26

36.The method of Claim 29 wherein said muscarinic antagonist is selected from the group consisting of darifenacin, tolterodine and oxybutynin or pharmaceutically acceptable salts thereof.

5

37.The method of Claim 29 wherein said muscarinic antagonist is darifenacin, or a pharmaceutically acceptable salt thereof.

38.The method of Claim 29 wherein said alpha-adrenoceptor antagonist is doxazosin and said muscarinic antagonist is darifenacin, or pharmaceutically acceptable salts of either thereof.

10

39.The method of Claim 29 wherein said alpha-adrenoceptor antagonist is 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline and said muscarinic antagonist is darifenacin, or pharmaceutically acceptable salts of either thereof.

15

10/2020 0623/2020